Tetsuya Takikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tetsuya Takikawa has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Kazuhiro Kikuta
14 shared publications- Ryotaro Matsumoto
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
12 shared publications - Atsushi Masamune
Division of Gastroenterology, Tohoku University Hospital, Sendai, Japan
11 shared publications Takanori Sano
11 shared publicationsAtsushi Masamune
8 shared publicationsShin Hamada
8 shared publications
Latest Publications
- Open Access
Diabetes Trajectory and Pancreatic Cancer Detection in Patients with Diabetes: A Nationwide Survey Through Japan Diabetes Society-Certified Facilities
Background/Objectives: Diabetes mellitus (DM) and pancreatic cancer (PC) have a bidirectional relationship. Although new-onset DM (NODM) is recognized as a potential clue to PC, worsening glycemic control in long-standing DM (LSDM) may also precede PC diagnosis. We aimed to characterize patterns of PC detection in specialist diabetes practice and to examine the association between diabetes-related diagnostic triggers and stage at diagnosis. Methods: This retrospective, nationwide, two-stage survey included patients with PC and DM treated at Japan Diabetes Society-certified educational facilities between 2017 and 2021. NODM and LSDM were defined as diabetes diagnosed within and more than 3 years before PC diagnosis, respectively. Results: Among 2291 patients with PC, 549 (24.0%) had NODM and 1742 (76.0%) had LSDM. Compared with symptom-based diagnosis, diabetes-related detection was associated with a higher proportion of stage 0/IA disease (11.0% vs. 3.9%) and a lower proportion of stage IV disease (26.1% vs. 49.5%). Diabetes-related detection was independently associated with stage 0/IA disease, with an adjusted odds ratio of 2.87 (95% confidence interval, 1.72–4.81; p < 0.001). Among patients with worsening LSDM, 57.2% were diagnosed with PC within 3 months and 79.4% within 6 months. Among those with available longitudinal body-weight data, 66.9% experienced weight loss of at least 2.5% compared with 1 year before PC diagnosis. Conclusions: Potential clues to PC in diabetes practice extend beyond NODM to deterioration of pre-existing diabetes, with weight loss frequently observed among patients with available longitudinal data. Prospective studies with appropriate control groups are needed to determine which diabetes trajectories can reliably identify patients who warrant targeted pancreatic evaluation.
Open AccessDiabetes Trajectory and Pancreatic Cancer Detection in Patients with Diabetes: A Nationwide Survey Through Japan Diabetes Society-Certified Facilities
Background/Objectives: Diabetes mellitus (DM) and pancreatic cancer (PC) have a bidirectional relationship. Although new-onset DM (NODM) is recognized as a potential clue to PC, worsening glycemic control in long-standing DM (LSDM) may also precede PC diagnosis. We aimed to characterize patterns of PC detection in specialist diabetes practice and to examine the association between diabetes-related diagnostic triggers and stage at diagnosis. Methods: This retrospective, nationwide, two-stage survey included patients with PC and DM treated at Japan Diabetes Society-certified educational facilities between 2017 and 2021. NODM and LSDM were defined as diabetes diagnosed within and more than 3 years before PC diagnosis, respectively. Results: Among 2291 patients with PC, 549 (24.0%) had NODM and 1742 (76.0%) had LSDM. Compared with symptom-based diagnosis, diabetes-related detection was associated with a higher proportion of stage 0/IA disease (11.0% vs. 3.9%) and a lower proportion of stage IV disease (26.1% vs. 49.5%). Diabetes-related detection was independently associated with stage 0/IA disease, with an adjusted odds ratio of 2.87 (95% confidence interval, 1.72–4.81; p < 0.001). Among patients with worsening LSDM, 57.2% were diagnosed with PC within 3 months and 79.4% within 6 months. Among those with available longitudinal body-weight data, 66.9% experienced weight loss of at least 2.5% compared with 1 year before PC diagnosis. Conclusions: Potential clues to PC in diabetes practice extend beyond NODM to deterioration of pre-existing diabetes, with weight loss frequently observed among patients with available longitudinal data. Prospective studies with appropriate control groups are needed to determine which diabetes trajectories can reliably identify patients who warrant targeted pancreatic evaluation.
- Open Access
- 29 June 2026
- Published by Springer Nature in Journal of Gastroenterology
- p. 1-12
Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of acute pancreatitis (AP). However, the clinical characteristics of AP in IBD and the differences between ulcerative colitis (UC) and Crohn’s disease (CD) remain unclear. Methods: We conducted a nationwide, multicenter, retrospective study at 28 institutions in Japan. Patients ≥ 16 years with UC or CD treated between 2012 and 2021 were included. We assessed the characteristics of AP in IBD, including differences between UC and CD. We also compared UC and CD patients with and without AP. Results: Among 24,849 patients with IBD (16,233 UC and 8,616 CD), 342 (1.4%) developed AP. Among these AP cases, severe AP and mortality were observed in 7.6% and 0.6%, respectively. Drug-induced AP was the most common etiology (55.6%), and autoimmune pancreatitis (AIP) ranked third (10.8%). Compared with UC, CD patients with AP had higher rates of intensive care unit admission ( P = 0.002) and severe AP ( P = 0.003). CD (odds ratio, 2.96; P = 0.02) and drug-induced or AIP etiology (odds ratio, 0.19; P < 0.001) were associated with severe AP. UC patients with AP had higher rates of pancolitis ( P < 0.001), extraintestinal manifestations ( P = 0.001), and steroid dependence ( P = 0.006) than those without AP. Conclusions: AP in IBD showed distinct clinical characteristics compared with AP in the general population. CD patients may develop more severe AP than UC, whereas UC patients with AP may have more aggressive and/or refractory disease features compared with those without AP.
- 29 June 2026
- Published by Springer Nature in Journal of Gastroenterology
- p. 1-12
Open AccessClinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of acute pancreatitis (AP). However, the clinical characteristics of AP in IBD and the differences between ulcerative colitis (UC) and Crohn’s disease (CD) remain unclear. Methods: We conducted a nationwide, multicenter, retrospective study at 28 institutions in Japan. Patients ≥ 16 years with UC or CD treated between 2012 and 2021 were included. We assessed the characteristics of AP in IBD, including differences between UC and CD. We also compared UC and CD patients with and without AP. Results: Among 24,849 patients with IBD (16,233 UC and 8,616 CD), 342 (1.4%) developed AP. Among these AP cases, severe AP and mortality were observed in 7.6% and 0.6%, respectively. Drug-induced AP was the most common etiology (55.6%), and autoimmune pancreatitis (AIP) ranked third (10.8%). Compared with UC, CD patients with AP had higher rates of intensive care unit admission ( P = 0.002) and severe AP ( P = 0.003). CD (odds ratio, 2.96; P = 0.02) and drug-induced or AIP etiology (odds ratio, 0.19; P < 0.001) were associated with severe AP. UC patients with AP had higher rates of pancolitis ( P < 0.001), extraintestinal manifestations ( P = 0.001), and steroid dependence ( P = 0.006) than those without AP. Conclusions: AP in IBD showed distinct clinical characteristics compared with AP in the general population. CD patients may develop more severe AP than UC, whereas UC patients with AP may have more aggressive and/or refractory disease features compared with those without AP.
- 19 March 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (3) , 469-478
Spink1 promotes the survival of Kras-mutant pancreatic acinar cells
- 19 March 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (3) , 469-478
Spink1 promotes the survival of Kras-mutant pancreatic acinar cells
- 20 November 2025
- Published by Elsevier in Pancreatology
- Vol. 26 (1) , 3-4
Pancreatic cancer: An urgent clinical challenge and opportunities for improved care
- 20 November 2025
- Published by Elsevier in Pancreatology
- Vol. 26 (1) , 3-4
Pancreatic cancer: An urgent clinical challenge and opportunities for improved care
- 13 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 823-831
Impact of coronavirus disease 2019 on the clinical outcomes of acute pancreatitis: a nationwide observational study in Japan
- 13 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 823-831
Impact of coronavirus disease 2019 on the clinical outcomes of acute pancreatitis: a nationwide observational study in Japan
- Open Access
- 2 May 2025
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 60 (8) , 1036-1046
Current status and trends in ERCP and post-ERCP pancreatitis in Japan: a nationwide observational study
Background: Endoscopic retrograde cholangiopancreatography (ERCP) is indispensable for the management of biliary and pancreatic diseases but carries a high risk of post-ERCP pancreatitis (PEP). This study aimed to clarify the current status and temporal trends of ERCP and PEP in Japan, including preventive measures. Methods: We conducted a retrospective, population-based cohort study using the Diagnosis Procedure Combination database from April 1, 2016, to March 31, 2023. Trend analyses were performed for ERCP, PEP, nonsteroidal anti-inflammatory drugs (NSAIDs), and protease inhibitors. Additionally, factors associated with PEP and severe PEP were evaluated. Results: Among the 1,073,513 ERCP cases, PEP and severe PEP incidences were 85,212 (7.9%) and 4841 cases (0.5%), respectively. The mortality rate was 0.5% for severe PEP and 0.2% for non-severe cases. The number of ERCP procedures and the proportion of therapeutic ERCP increased over time. The incidence of PEP declined from 9.1% in the fiscal year 2016–2017 to 6.4% in the fiscal year 2022, while the incidence of severe PEP decreased from 0.5 to 0.33% over the same period. The usage rate of rectal NSAIDs increased from 16.4 to 27.6%, whereas that of protease inhibitors decreased from 70.5 to 53.5%. The administration of rectal NSAIDs at doses of 20–25 mg and 50 mg was associated with a reduced risk of severe PEP. Conclusions: The number of ERCP procedures and the proportion of therapeutic ERCP have increased, whereas the incidences of PEP and severe PEP have decreased. Rectal NSAIDs may prevent the progression of PEP to severe disease.
- 2 May 2025
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 60 (8) , 1036-1046
Open AccessCurrent status and trends in ERCP and post-ERCP pancreatitis in Japan: a nationwide observational study
Background: Endoscopic retrograde cholangiopancreatography (ERCP) is indispensable for the management of biliary and pancreatic diseases but carries a high risk of post-ERCP pancreatitis (PEP). This study aimed to clarify the current status and temporal trends of ERCP and PEP in Japan, including preventive measures. Methods: We conducted a retrospective, population-based cohort study using the Diagnosis Procedure Combination database from April 1, 2016, to March 31, 2023. Trend analyses were performed for ERCP, PEP, nonsteroidal anti-inflammatory drugs (NSAIDs), and protease inhibitors. Additionally, factors associated with PEP and severe PEP were evaluated. Results: Among the 1,073,513 ERCP cases, PEP and severe PEP incidences were 85,212 (7.9%) and 4841 cases (0.5%), respectively. The mortality rate was 0.5% for severe PEP and 0.2% for non-severe cases. The number of ERCP procedures and the proportion of therapeutic ERCP increased over time. The incidence of PEP declined from 9.1% in the fiscal year 2016–2017 to 6.4% in the fiscal year 2022, while the incidence of severe PEP decreased from 0.5 to 0.33% over the same period. The usage rate of rectal NSAIDs increased from 16.4 to 27.6%, whereas that of protease inhibitors decreased from 70.5 to 53.5%. The administration of rectal NSAIDs at doses of 20–25 mg and 50 mg was associated with a reduced risk of severe PEP. Conclusions: The number of ERCP procedures and the proportion of therapeutic ERCP have increased, whereas the incidences of PEP and severe PEP have decreased. Rectal NSAIDs may prevent the progression of PEP to severe disease.
- 12 September 2024
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (1) , e30-e38
Risk Factors and a Prediction Model for Pain Recurrence After Pancreatic Stent Removal in Painful Chronic Pancreatitis
Objectives: Endoscopic pancreatic stenting (EPS) is an effective treatment for painful chronic pancreatitis. However, little is known about the factors that cause pain recurrence after stent removal, and there are no clear criteria for stent removal. We aimed to develop a prediction model for pain recurrence by identifying its risk factors. Materials and Methods: We retrospectively reviewed 95 patients who underwent EPS for pain for the first time using a single plastic stent between January 2007 and July 2022 at our institute. Univariate and multivariate stepwise Cox proportional hazards models were used to identify the risk factors for pain recurrence, and a prediction model was developed based on the identified factors. Results: Of the 95 enrolled patients, 89 (93.7%) achieved pain relief and 73 (76.8%) did stent removal. Among 69 patients with a follow-up period ≥6 months after stent removal, 29 (42.0%) had pain recurrence during the median follow-up of 59 months. Serum lipase level (P = 0.034) and pancreatic parenchymal thickness (P = 0.022) on computed tomography or magnetic resonance imaging were identified as independent risk factors for pain recurrence. The prediction model based on the identified factors had good discrimination ability, with a concordance index of 0.74, and could stratify pain recurrence rates. Conclusions: We identified the risk factors and developed a new prediction model for pain recurrence following stent removal. This model might be useful for decision making in pancreatic stent management, such as deciding whether to remove a stent, continue EPS, or convert to surgery.
- 12 September 2024
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (1) , e30-e38
Risk Factors and a Prediction Model for Pain Recurrence After Pancreatic Stent Removal in Painful Chronic Pancreatitis
Objectives: Endoscopic pancreatic stenting (EPS) is an effective treatment for painful chronic pancreatitis. However, little is known about the factors that cause pain recurrence after stent removal, and there are no clear criteria for stent removal. We aimed to develop a prediction model for pain recurrence by identifying its risk factors. Materials and Methods: We retrospectively reviewed 95 patients who underwent EPS for pain for the first time using a single plastic stent between January 2007 and July 2022 at our institute. Univariate and multivariate stepwise Cox proportional hazards models were used to identify the risk factors for pain recurrence, and a prediction model was developed based on the identified factors. Results: Of the 95 enrolled patients, 89 (93.7%) achieved pain relief and 73 (76.8%) did stent removal. Among 69 patients with a follow-up period ≥6 months after stent removal, 29 (42.0%) had pain recurrence during the median follow-up of 59 months. Serum lipase level (P = 0.034) and pancreatic parenchymal thickness (P = 0.022) on computed tomography or magnetic resonance imaging were identified as independent risk factors for pain recurrence. The prediction model based on the identified factors had good discrimination ability, with a concordance index of 0.74, and could stratify pain recurrence rates. Conclusions: We identified the risk factors and developed a new prediction model for pain recurrence following stent removal. This model might be useful for decision making in pancreatic stent management, such as deciding whether to remove a stent, continue EPS, or convert to surgery.
- 19 January 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (3) , 335-342
Maintenance steroid therapy is associated with decreased risk of malignancy and better prognosis of patients with autoimmune pancreatitis: A multicenter cohort study in Japan
- 19 January 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (3) , 335-342
Maintenance steroid therapy is associated with decreased risk of malignancy and better prognosis of patients with autoimmune pancreatitis: A multicenter cohort study in Japan
- 6 January 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (2) , 197-205
Skeletal muscle mass and function are affected by pancreatic atrophy, pancreatic exocrine insufficiency and poor nutritional status in patients with chronic pancreatitis
- 6 January 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (2) , 197-205
Skeletal muscle mass and function are affected by pancreatic atrophy, pancreatic exocrine insufficiency and poor nutritional status in patients with chronic pancreatitis